- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mi | Gain Therapeutics reports biomarker data from Parkinson's trial | 1 | Investing.com | ||
| Mi | Gain Therapeutics legt vielversprechende Biomarker-Daten aus Parkinson-Studie vor | 4 | Investing.com Deutsch | ||
| Mi | Gain Therapeutics, Inc.: Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 | 2 | GlobeNewswire (USA) | ||
| 03.02. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.01. | Gain Therapeutics reports 81% reduction in Parkinson's biomarker | 13 | Investing.com | ||
| 22.12.25 | Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data | 1 | Investing.com | ||
| 18.12.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease | 3 | GlobeNewswire (USA) | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.12.25 | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.25 | Gain Therapeutics, Inc.: Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease | 485 | GlobeNewswire (Europe) | Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever... ► Artikel lesen | |
| 03.12.25 | Gain Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 01.12.25 | H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data | 12 | Investing.com | ||
| 28.11.25 | Gain Therapeutics reicht Prospektnachtrag für Aktienangebot über 35,5 Mio. USD ein | 2 | Investing.com Deutsch | ||
| 28.11.25 | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.11.25 | Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 | 1 | Seeking Alpha | ||
| 16.10.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Attend the 2025 Maxim Growth Summit | 4 | GlobeNewswire (USA) | ||
| 14.10.25 | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.10.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease | 2 | GlobeNewswire (USA) | ||
| 06.10.25 | Gain Therapeutics meldet vorläufige Phase-1b-Daten für Parkinson-Medikament GT-02287 | 2 | Investing.com Deutsch |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAGE LABS | 16,100 | -3,59 % | AKTIONÄR-Tipp BioAge Labs wird entdeckt: 272 Prozent Kurspotenzial! | Der Megatrend Longevity hat nun auch die Aktie von BioAge Labs erfasst. Ausgehend vom 52-Wochen-Tief bei 2,88 Dollar konnte sich der Titel auf aktuell 19,60 Dollar zuletzt vervielfachen. Und die Analysten... ► Artikel lesen | |
| QUINCE THERAPEUTICS | 0,089 | +5,06 % | Quince Therapeutics, Inc. - 8-K, Current Report | ||
| FRACTYL HEALTH | 0,432 | -1,03 % | FRACTYL HEALTH, INC. - 8-K, Current Report | ||
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,68 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| IMMUNOVANT | 22,980 | -2,69 % | Bernstein initiates Immunovant stock coverage with neutral rating | ||
| KYMERA THERAPEUTICS | 77,91 | -2,06 % | Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 | ||
| NURIX THERAPEUTICS | 14,430 | -3,25 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 60,92 | -5,18 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| QIAGEN | 34,805 | -1,28 % | Qiagen unter Druck, Zalando auf Erholungskurs: DAX-Ausblick | Der DAX befindet sich weiter auf Talfahrt. In der abgelaufenen Woche büßte das größte deutsche Börsenbarometer rund 144 Punkte ein und schloss -0,61% niedriger mit 23.447 Punkten. Die höchsten Verluste... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,210 | +0,54 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,170 | -0,85 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,000 | +1,13 % | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20... ► Artikel lesen | |
| IMMIX BIOPHARMA | 9,110 | -5,89 % | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD Confirms Immix, AWS, and Circadian Risk Participation at ISC West 2026 | Detroit, Michigan--(Newsfile Corp. - February 12, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the "Company"), a global leader in AI-driven security and productivity... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 46,080 | +0,96 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,925 Euro und damit +1,32 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.